About: Increased mortality of acute respiratory distress syndrome was associated with high levels of plasma phenylalanine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Increased mortality of acute respiratory distress syndrome was associated with high levels of plasma phenylalanine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Increased mortality of acute respiratory distress syndrome was associated with high levels of plasma phenylalanine
Creator	Zhang, Yi Wang, Xiaoli Wang, Jie Chen, Hong Xu, Jing Liu, Jialin Liu, Zhaojun Pan, Tingting Qu, Hongping Tan, Ruoming Zhang, Jingjing Qi, Xiaoling Tao, Zheying Wang, Yihui
Source	PMC
abstract	BACKGROUND: There is a dearth of drug therapies available for the treatment of acute respiratory distress syndrome (ARDS). Certain metabolites play a key role in ARDS and could serve as potential targets for developing therapies against this respiratory disorder. The present study was designed to determine such “functional metabolites” in ARDS using metabolomics and in vivo experiments in a mouse model. METHODS: Metabolomic profiles of blood plasma from 42 ARDS patients and 28 healthy controls were captured using Ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) assay. Univariate and multivariate statistical analysis were performed on metabolomic profiles from blood plasma of ARDS patients and healthy controls to screen for “functional metabolites”, which were determined by variable importance in projection (VIP) scores and P value. Pathway analysis of all the metabolites was performed. The mouse model of ARDS was established to investigate the role of “functional metabolites” in the lung injury and mortality caused by the respiratory disorder. RESULTS: The metabolomic profiles of patients with ARDS were significantly different from healthy controls, difference was also observed between metabolomic profiles of the non-survivors and the survivors among the ARDS patient pool. Levels of Phenylalanine, D-Phenylalanine and Phenylacetylglutamine were significantly increased in non-survivors compared to the survivors of ARDS. Phenylalanine metabolism was the most notably altered pathway between the non-survivors and survivors of ARDS patients. In vivo animal experiments demonstrated that high levels of Phenylalanine might be associated with the severer lung injury and increased mortality of ARDS. CONCLUSION: Increased mortality of acute respiratory distress syndrome was associated with high levels of plasma Phenylalanine. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800015930. Registered 29 April 2018, http://www.chictr.org.cn/edit.aspx?pid=25609&htm=4
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.1186/s12931-020-01364-6
bibo:pmid	32354336
has license	cc-by
sha1sum (hex)	f50fbd04a6d67112b0d73ff941f7406b610f948e
schema:url	https://doi.org/10.1186/s12931-020-01364-6
resource representing a document's title	Increased mortality of acute respiratory distress syndrome was associated with high levels of plasma phenylalanine
has PubMed Central identifier	PMC7193408
has PubMed identifier	32354336
schema:publication	Respir Res
resource representing a document's body	covid:f50fbd04a6d67112b0d73ff941f7406b610f948e#body_text
is schema:about of	named entity 'PLAY' named entity 'IS A' covid:arg/f50fbd04a6d67112b0d73ff941f7406b610f948e named entity 'key role' named entity 'ARDS' named entity 'ARDS' named entity 'respiratory disorder' named entity 'metabolomics' named entity 'acute respiratory distress syndrome' named entity 'metabolites' named entity 'phenylalanine' named entity 'high levels' named entity 'sonicated' named entity 'inflammatory diseases' named entity 'metabolites' named entity 'acute respiratory distress syndrome' named entity 'infection' named entity 'metabolomic' named entity 'room temperature' named entity 'Agilent Technologies' named entity 'PLS' named entity 'phenylacetylglutamine' named entity 'Phenylacetylglutamine' named entity 'MS/MS' named entity 'ARDS' named entity 'mouse model' named entity 'metabolites' named entity 'mouse model' named entity 'upregulation' named entity 'Phenylalanine' named entity 'ARDS' named entity 'infection' named entity 'platelets' named entity 'biosynthesis' named entity 'Univariate Analysis' named entity 'metabolites' named entity 'ROC' named entity 'inflammatory responses' named entity 'mzXML' named entity 'prognosis' named entity 'peptide' named entity 'ARDS' named entity 'Platelets' named entity 'PLS' named entity 'KEGG' named entity 'Survival analysis' named entity 'protein' named entity 'bronchoalveolar lavage fluid' named entity 'PHA' named entity 'PBS' named entity 'ARDS' named entity 'Statistically significant' named entity 'AJS' named entity 'ATCC' named entity 'therapeutic targets' named entity 'AUC' named entity 'Metabolites' named entity 'Phenylalanine' named entity 'intensive care units' named entity 'Phenylalanine' named entity 'hematoxylin and eosin' named entity 'ARDS' named entity 'white cell' named entity 'phenylacetylglutamine' named entity 'Gly' named entity 'mmol/L' named entity 'plasma collection' named entity 'plasma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software